Repeated intravitreal bevacizumab (AvastinÂ) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation

Acta Ophthalmologica

Volumn 89, Issue 1, 2011, Pages 76-81

  Schmidinger, Gerald ^a   Maar, Noemi ^a   Bolz, Matthias ^a   Scholda, Christoph ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

anti VEGF treatment; bevacizumab; panretinal lasercoagulation; proliferative diabetic retinopathy

Indexed keywords

BEVACIZUMAB; DEXAGENTA POS; DEXAMETHASONE; GENTAMICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; COLOR FUNDUS PHOTOGRAPHY; DIABETIC RETINOPATHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LASER COAGULATION; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTOGRAPHY; PRIORITY JOURNAL; RETINA BLOOD VESSEL;

EID: 79551566731     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01622.x     Document Type: Article

References (21)

1. Adamis AP, Altaweel M, Bressler NM, et al. (2006): Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113: 23-28.
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. (2007): Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114: 743-750.
3. Avery RL, Pearlman J, Pieramici DJ, et al. (2006): Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695e1-1695e15.
4. Bakri SJ, Donaldson MJ, &, Link TP, (2006): Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20: 1474-1475.
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, &, Singh RJ, (2007): Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859.
6. Chen E, &, Park CH, (2006): Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26: 699-700.
7. Chen CY, Wong TY, &, Heriot WJ, (2007): Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 143: 510-512.
8. Chun DW, Heier JS, Topping TM, Duker JS, &, Bankert JM, (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 1706-1712.
9. Emerson MV, Lauer AK, Flaxel CJ, et al. (2007): Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27: 439-444.
10. Early Treatment Diabetic Retinopathy Study Research Group (1991): Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 98: 766-785.
11. Diabetic Retinopathy Study Group (1978): Photocoagulation treatment of proliferative diabetic retinopathy: the second report from the Diabetic Retinopathy Study. Arch Ophthalmol 85: 81-106.
12. Isaacs TW, &, Barry C, (2006): Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 34: 802-803.
13. Jorge R, Costa RA, Calucci D, Cintra LP, &, Scott IU, (2006): Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26: 1006-1013.
14. Karacorlu M, Ozdemir H, Karacorlu S, &, Alacali N, (2004): Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. Int Ophthalmol 25: 113-116.
15. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, &, Venkatraman AS, (2005): Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035-1047.
16. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, &, Balestrazzi E, (2008): Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 86: 683-687.
17. Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, &, Mishima HK, (2006): Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244: 309-315.
18. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, &, Matsumura M, (2002): Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 134: 348-353.
19. Oshima Y, Sakaguchi H, Gomi F, &, Tano Y, (2006): Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142: 155-158.
20. Spaide RF, &, Fisher YL, (2006): Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26: 275-278.
21. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, &, Jorge R, (2008): Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 86: 385-389.